{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:21:53Z","timestamp":1760955713419},"reference-count":29,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1536\/ihj.16-222","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T18:08:10Z","timestamp":1489687690000},"page":"167-173","source":"Crossref","is-referenced-by-count":3,"title":["Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI"],"prefix":"10.1536","volume":"58","author":[{"given":"Xi","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital, Sun Yat-Sen University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Xin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Gang","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Hong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Levine GN, Bates ER, Blankenship JC, <i>et al<\/i>. 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44-122.","DOI":"10.1016\/j.jacc.2011.08.007"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Matetzky S, Shenkman B, Guetta V, <i>et al<\/i>. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.","DOI":"10.1161\/01.CIR.0000130846.46168.03"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gurbel PA, Bliden KP, Guyer K, <i>et al<\/i>. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-6.","DOI":"10.1016\/j.jacc.2005.07.041"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-66.","DOI":"10.1016\/j.jacc.2006.10.050"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009; 27: 259-74.","DOI":"10.1111\/j.1755-5922.2009.00096.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2014; 34: 1077-90. (Review)","DOI":"10.1002\/phar.1477"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wallentin L, Becker RC, Budaj A, <i>et al<\/i>. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.","DOI":"10.1056\/NEJMoa0904327"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Marcucci R, Gori AM, Paniccia R, <i>et al<\/i>. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-42.","DOI":"10.1161\/CIRCULATIONAHA.108.812636"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Price MJ, Endemann S, Gollapudi RR, <i>et al<\/i>. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.","DOI":"10.1093\/eurheartj\/ehn046"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rao SV, O\u2019Grady K, Pieper KS, <i>et al<\/i>. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-6.","DOI":"10.1016\/j.amjcard.2005.06.056"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bovill EG, Terrin ML, Stump DC, <i>et al<\/i>. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991; 115: 256-65.","DOI":"10.7326\/0003-4819-115-4-256"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Matetzky S, Shenkman B, Guetta V, <i>et al<\/i>. Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction. Circulation 2004; 109: 3171-5.","DOI":"10.1161\/01.CIR.0000130846.46168.03"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cuisset T, Frere C, Quilici J, <i>et al<\/i>. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-9.","DOI":"10.1111\/j.1538-7836.2005.01751.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nishio R, Shinke T, Morino Y, <i>et al<\/i>. Early phase arterial reaction following drug-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. Int Heart J 2015; 56: 389-94.","DOI":"10.1536\/ihj.15-044"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zhang J. Stent thrombosis in patients with coronary artery disease treated with biodegradable polymer drug-eluting stents: an update meta-analysis. Int Heart J 2014; 55: 213-8. (Review)","DOI":"10.1536\/ihj.13-322"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Zhang HZ, Kim MH, Jeong YH. Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets 2014; 25: 292-9.","DOI":"10.3109\/09537104.2013.815341"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010; 8: 2140-8.","DOI":"10.1111\/j.1538-7836.2010.04017.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19. Patti G, Nusca A, Mangiacapra F, Gatto L, D\u2019Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008; 52: 1128-33.","DOI":"10.1016\/j.jacc.2008.06.038"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20. Valgimigli M, Campo G, de Cesare N, <i>et al<\/i>. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and\/or Resistance to Clopidogrel study. Circulation 2009; 119: 3215-22.","DOI":"10.1161\/CIRCULATIONAHA.108.833236"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21. VAN Giezen JJ, Nilsson L, Berntsson P, <i>et al<\/i>. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009; 7: 1556-65.","DOI":"10.1111\/j.1538-7836.2009.03527.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22. Gurbel PA, Bliden KP, Butler K, <i>et al<\/i>. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-99.","DOI":"10.1161\/CIRCULATIONAHA.109.919456"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23. Alexopoulos D, Galati A, Xanthopoulou I, <i>et al<\/i>. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 2012; 60: 193-9.","DOI":"10.1016\/j.jacc.2012.03.050"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24. Steg PG, Harrington RA, Emanuelsson H, <i>et al<\/i>. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013; 128: 1055-65.","DOI":"10.1161\/CIRCULATIONAHA.113.002589"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099-106.","DOI":"10.1161\/01.CIR.0000161383.06692.D4"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26. Angiolillo DJ, Shoemaker SB, Desai B, <i>et al<\/i>. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-16.","DOI":"10.1161\/CIRCULATIONAHA.106.667741"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, <i>et al<\/i>. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-42.","DOI":"10.1056\/NEJMoa0909475"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28. Price MJ, Berger PB, Teirstein PS, <i>et al<\/i>. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-105.","DOI":"10.1001\/jama.2011.290"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29. Kohli P, Wallentin L, Reyes E, <i>et al<\/i>. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation 2013; 127: 673-80.","DOI":"10.1161\/CIRCULATIONAHA.112.124248"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30. DiNicolantonio JJ, Tomek A. Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. Int J Cardiol 2013; 169: 145-6.","DOI":"10.1016\/j.ijcard.2013.08.085"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/2\/58_16-222\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T17:16:47Z","timestamp":1568913407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/2\/58_16-222\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.16-222","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}